The findings show that most people with psoriasis reported to PsoProtect who are taking drugs that affect the immune system fully recover from COVID-19.
People with psoriasis who are taking drugs that affect the
immune system have high rates of recovery from COVID-19, according to the first
from the global registry of patients with psoriasis and COVID-19
The researchers found that the risk factors of hospitalisation
for COVID-19 (an indicator of severe infection) reported to the registry were
similar to the general population.
These findings come from the first analysis of the
PsoProtect registry, featuring data from 374 patients with either suspected or
confirmed COVID-19 infection, reported by their clinicians. The PsoProtect
registry was established by dermatologists and researchers at St John’s
Institute of Dermatology at Guy’s & St Thomas’ NHS Foundation Trust and
King’s College London, and the University of Manchester to understand how
psoriasis and the medications that are used to treat it might influence the
severity of COVID-19 infection. PsoProtect is supported by psoriasis patient
support organisations throughout the world, including the Psoriasis
Helen McAteer, Chief Executive of the Psoriasis Association
said ”From the beginning of the pandemic
we understood the importance of being proactive in order to address the many
concerns expressed to us by people who are living with psoriasis. The
PsoProtect registry is vital in helping us understand more about the
interactions between psoriasis, its treatments and COVID-19 infection so
patients can make the most informed choices about their care and treatment at
this challenging time.”
Here is a short summary of the research findings:
PsoProtect, a global registry for
healthcare professionals to record information about their patients’
experiences, was set up in order to understand the impact that treatments for
psoriasis may have on recovery from COVID-19.
Information on 374 patients with psoriasis and
COVID-19 from 25 countries was collected in PsoProtect (up to 1st
July 2020). Most of the patients (334, 89%) were taking treatments for
their psoriasis that affect the immune system – either injection treatments
known as ‘biologics’ that target specific immune proteins (267 patients, 71%)
or traditional tablet immunosuppressants (67, 18%).
Patients who were older, male, of non-white
ethnicity and with other health conditions were more likely to require
admission to hospital for their COVID-19 infection. This suggests that people
with psoriasis have similar risk factors for more severe infection to the
biologics for psoriasis were less frequently hospitalised than those receiving traditional
we do not know that this association is causal. There may be some other factor
that is associated with taking a biologic drug – for example very careful
social distancing, or shielding – that is actually causing the reduced risk. It
could also be that the population of patients in the PsoProtect registry is not
representative of the whole population of people with psoriasis who are taking
drugs that affect the immune system.
Further research is needed before
concluding that biologics are safer than traditional immunosuppressants in the
context of COVID-19, but in the meantime these findings are reassuring.
End of summary
read the full paper here.
If you are a healthcare professional treating patients with psoriasis, please continue to report cases of suspected or confirmed COVID-19 infection in your patients here.
If you have psoriasis yourself, you can report your experiences of life during the COVID-19 pandemic (whether or not you have had symptoms of COVID-19) here.